Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

被引：158

作者：

Ji, Li-Nong ^{[1
]}

Lu, Ju-Ming ^{[2
]}

Guo, Xiao-Hui ^{[3
]}

Yang, Wen-Ying ^{[4
]}

Weng, Jian-Ping ^{[5
]}

Jia, Wei-Ping ^{[6
]}

Zou, Da-Jin ^{[7
]}

Zhou, Zhi-Guang ^{[8
]}

Yu, De-Min ^{[9
]}

Liu, Jie ^{[10
]}

Shan, Zhong-Yan ^{[11
]}

Yang, Yu-Zhi ^{[12
]}

Hu, Ren-Ming ^{[13
]}

Zhu, Da-Long ^{[14
]}

Yang, Li-Yong ^{[15
]}

Chen, Li ^{[16
]}

Zhao, Zhi-Gang ^{[17
]}

Li, Qi-Fu ^{[18
]}

Tian, Hao-Ming ^{[19
]}

Ji, Qiu-He ^{[20
]}

Liu, Jing ^{[21
]}

Ge, Jia-Pu ^{[22
]}

Shi, Li-Xin ^{[23
]}

Xu, Yan-Cheng ^{[24
]}

机构：

[1] Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing, Peoples R China

[3] Peking Univ, Hosp 1, Dept Endocrinol, Beijing, Peoples R China

[4] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China

[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China

[6] Shanghai Sixth Peoples Hosp, Dept Endocrinol, Shanghai, Peoples R China

[7] Second Mil Med Univ, Changhai Hosp, Dept Endocrinol, Shanghai, Peoples R China

[8] Cent South Univ, Xiangya Hosp 2, Dept Endocrinol, Changsha, Hunan, Peoples R China

[9] Tianjin Med Univ, Metab Dis Hosp, Dept Endocrinol, Tianjin, Peoples R China

[10] Shanxi Prov Peoples Hosp, Dept Endocrinol, Taiyuan, Peoples R China

[11] China Med Univ, Hosp 1, Dept Endocrinol, Shenyang, Peoples R China

[12] Heilongjiang Prov Hosp, Dept Endocrinol, Harbin, Peoples R China

[13] Fudan Univ, Huashan Hosp, Dept Endocrinol, Shanghai 200433, Peoples R China

[14] Nanjing Univ, Sch Med, Affiliated Hosp, Dept Endocrinol,Nanjing Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China

[15] Fujian Med Univ, Affiliated Hosp 1, Dept Endocrinol, Fuzhou, Peoples R China

[16] Shandong Univ, Qilu Hosp, Dept Endocrinol, Jinan 250100, Peoples R China

[17] Henan Prov Peoples Hosp, Dept Endocrinol, Zhengzhou, Peoples R China

[18] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Chongqing, Peoples R China

[19] Sichuan Univ, West China Hosp, Dept Endocrinol, Chengdu 610064, Peoples R China

[20] Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian 710032, Peoples R China

[21] Gansu Prov Hosp, Dept Endocrinol, Lanzhou, Peoples R China

[22] Xinjiang Uigur Autonomous Reg Peoples Hosp, Dept Endocrinol, Urumqi, Peoples R China

[23] Guiyang Med Coll, Affiliated Hosp, Dept Endocrinol, Guiyang, Peoples R China

[24] Wuhan Univ, Zhongnan Hosp, Dept Endocrinol, Wuhan 430072, Peoples R China

来源：

BMC PUBLIC HEALTH | 2013年 / 13卷

关键词：

China; GLP-1 receptor agonists; HbA1c; Insulin; Oral antidiabetes drugs (OADs); Type 2 diabetes mellitus; MANAGEMENT; DETERMINANTS; ASSOCIATION; STATEMENT; COLLEGE;

D O I：

10.1186/1471-2458-13-602

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

100235 [预防医学];

摘要：

Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly among Chinese adults, and limited data are available on T2DM management and the status of glycemic control in China. We assessed the efficacy of oral antidiabetes drugs (OADs), glucagon-like peptide-1 (GLP-1) receptor agonists, and insulin for treatment of T2DM across multiple regions in China. Methods: This was a multicenter, cross-sectional survey of outpatients conducted in 606 hospitals across China. Data from all the patients were collected between April and June, 2011. Results: A total of 238,639 patients were included in the survey. Eligible patients were treated with either OADs alone (n=157,212 [65.88%]), OADs plus insulin (n=80,973 [33.93%]), or OADs plus GLP-1 receptor agonists (n=454 [0.19%]). The OAD monotherapy, OAD + insulin, and OAD + GLP-1 receptor agonist groups had mean glycosylated hemoglobin (HbA1c) levels (+/- SD) of 7.67% (+/- 1.58%), 8.21% (+/- 1.91%), and 7.80% (+/- 1.76%), respectively. Among those three groups, 34.63%, 26.21%, and 36.12% met the goal of HbA1c <7.0%, respectively. Mean HbA1c and achievement of A1c <7.0% was related to the duration of T2DM. Conclusions: Less than one third of the patients had achieved the goal of HbA1c <7.0%. Glycemic control decreased and insulin use increased with the duration of diabetes.

引用

页数：8

共 18 条

[1]

Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]

[2]

[Anonymous], 2011, LANCET, V378, P457, DOI 10.1016/S0140-6736(11)61232-4

[3]

[Anonymous], CHIN J DIABETES M S2

[4]

The Status of Glycemic Control: A Cross-Sectional Study of Outpatients With Type 2 Diabetes Mellitus Across Primary, Secondary, and Tertiary Hospitals in the Jiangsu Province of China [J].